176 related articles for article (PubMed ID: 33737678)
1. Population pharmacokinetic model development and its relationship with adverse events of oxcarbazepine in adult patients with epilepsy.
Jang Y; Yoon S; Kim TJ; Lee S; Yu KS; Jang IJ; Chu K; Lee SK
Sci Rep; 2021 Mar; 11(1):6370. PubMed ID: 33737678
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy.
Chen CY; Zhou Y; Cui YM; Yang T; Zhao X; Wu Y
J Clin Pharm Ther; 2019 Apr; 44(2):300-311. PubMed ID: 30636182
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens.
Lin WW; Li XW; Jiao Z; Zhang J; Rao X; Zeng DY; Lin XH; Wang CL
Eur J Clin Pharmacol; 2019 Mar; 75(3):381-392. PubMed ID: 30456415
[TBL] [Abstract][Full Text] [Related]
4. Glomerular Filtration Rate Is a Major Predictor of Clearance of Oxcarbazepine Active Metabolite in Adult Chinese Epileptic Patients: A Population Pharmacokinetic Analysis.
Lin WW; Wang CL; Jiao Z; Yu XL; Zhang J; Zhang WB; Lin RF; Lin S; Lin XH
Ther Drug Monit; 2019 Oct; 41(5):665-673. PubMed ID: 31033858
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of oral loading of oxcarbazepine suspension in selected patients with epilepsy.
Kim DW; Gu N; Lee H; Jang IJ; Chu K; Yu KS; Cho JY; Yoon SH; Na HJ; Lee SK
Int J Clin Pharmacol Ther; 2013 Oct; 51(10):780-6. PubMed ID: 23849326
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric epileptic patients shows no difference between Japanese and other ethnicities.
Sugiyama I; Bouillon T; Yamaguchi M; Suzuki H; Hirota T; Fink M
Drug Metab Pharmacokinet; 2015 Apr; 30(2):160-7. PubMed ID: 25989891
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy.
Peng J; Zhang HN; Liu ZS; Xu H; Wang Y
Int J Clin Pharmacol Ther; 2014 Aug; 52(8):684-92. PubMed ID: 24887335
[TBL] [Abstract][Full Text] [Related]
8. Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy.
Lu Y; Fang Y; Wu X; Ma C; Wang Y; Xu L
Eur J Clin Pharmacol; 2017 Mar; 73(3):307-315. PubMed ID: 27900402
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Adverse Drug Reactions with Carbamazepine and Oxcarbazepine at a Tertiary Care Hospital.
Lee JE; Min KR; Kim SH; Kim AH; Kim ST
Yonsei Med J; 2020 Oct; 61(10):875-879. PubMed ID: 32975062
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy.
Yu Y; Zhang Q; Xu W; Lv C; Hao G
Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):345-51. PubMed ID: 25700977
[TBL] [Abstract][Full Text] [Related]
11. Symptomatology of carbamazepine- and oxcarbazepine-induced hyponatremia in people with epilepsy.
Berghuis B; Hulst J; Sonsma A; McCormack M; de Haan GJ; Sander JW; Lindhout D; Koeleman BPC
Epilepsia; 2021 Mar; 62(3):778-784. PubMed ID: 33576502
[TBL] [Abstract][Full Text] [Related]
12. Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcarbazepine therapy.
Striano S; Striano P; Di Nocera P; Italiano D; Fasiello C; Ruosi P; Bilo L; Pisani F
Epilepsy Res; 2006 May; 69(2):170-6. PubMed ID: 16515857
[TBL] [Abstract][Full Text] [Related]
13. Relationship between mono-hydroxy-carbazepine serum concentrations and adverse effects in patients on oxcarbazepine monotherapy.
Sattler A; Schaefer M; May TW
Seizure; 2015 Sep; 31():149-54. PubMed ID: 26362393
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy.
Li X; Wei S; Wu H; Zhang Q; Zhao Z; Mei S; Feng W; Wu Y
Eur J Pediatr; 2023 Oct; 182(10):4509-4521. PubMed ID: 37493972
[TBL] [Abstract][Full Text] [Related]
15. Comparison of oxcarbazepine efficacy and MHD concentrations relative to age and BMI: Associations among ABCB1, ABCC2, UGT2B7, and SCN2A polymorphisms.
Yang X; Yan Y; Fang S; Zeng S; Ma H; Qian L; Chen X; Wei J; Gong Z; Xu Z
Medicine (Baltimore); 2019 Mar; 98(12):e14908. PubMed ID: 30896644
[TBL] [Abstract][Full Text] [Related]
16. Comparison of long-term efficacy, tolerability, and safety of oxcarbazepine, lamotrigine, and levetiracetam in patients with newly diagnosed focal epilepsy: An observational study in the real world.
Li R; Zhou Q; Ou S; Wang Y; Li Y; Xia L; Pan S
Epilepsy Res; 2020 Oct; 166():106408. PubMed ID: 32679487
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children.
Rodrigues C; Chiron C; Rey E; Dulac O; Comets E; Pons G; Jullien V
Br J Clin Pharmacol; 2017 Dec; 83(12):2695-2708. PubMed ID: 28771787
[TBL] [Abstract][Full Text] [Related]
18. Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis.
Bae EK; Lee J; Shin JW; Moon J; Lee KJ; Shin YW; Kim TJ; Shin D; Jang IJ; Lee SK
Seizure; 2016 Apr; 37():8-12. PubMed ID: 26908152
[TBL] [Abstract][Full Text] [Related]
19. Saliva and Plasma Monohydroxycarbamazepine Concentrations in Pediatric Patients With Epilepsy.
Li RR; Sheng XY; Ma LY; Yao HX; Cai LX; Chen CY; Zhu SN; Zhou Y; Wu Y; Cui YM
Ther Drug Monit; 2016 Jun; 38(3):365-70. PubMed ID: 26818624
[TBL] [Abstract][Full Text] [Related]
20. [Oxcarbazepine in the treatment of epilepsy. A review and update].
Horga de la Parte JF; Horga A
Rev Neurol; 2006 Jan 16-31; 42(2):95-113. PubMed ID: 16450324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
